Menadione

When Menadione was standardly prescribed for adults, the dosage was highly individualized based on the patient's Prothrombin Time (PT) and International Normalized Ratio (INR).

• For Vitamin K Deficiency: The typical adult dose ranged from 2 mg to 5 mg per day, administered orally.
• For Hypoprothrombinemia secondary to drugs (excluding anticoagulants): 2.5 mg to 10 mg per day may have been used.
• Injectable Dosing: In acute settings, 5 mg to 10 mg could be administered via intramuscular injection, though this carried a higher risk of adverse reactions.

Caution: Menadione is generally NOT recommended for pediatric use, especially in neonates (newborns).

• Neonates: Use is strictly contraindicated due to the high risk of hyperbilirubinemia (excess bilirubin in the blood) and kernicterus (brain damage caused by jaundice).
• Older Children: If prescribed, doses were significantly lower (e.g., 1 mg to 2 mg) and required constant monitoring of hematological parameters.

Renal Impairment

There are no specific dosage adjustments provided in historical labeling for renal impairment; however, since metabolites are excreted renally, caution is advised. Healthcare providers typically monitor for signs of accumulation or toxicity in patients with Stage 4 or 5 Chronic Kidney Disease (CKD).

Hepatic Impairment

Patients with impaired liver function may not respond to Menadione therapy. If the liver is severely damaged, it cannot synthesize clotting factors regardless of the amount of Vitamin K available. Furthermore, the liver's ability to conjugate and detoxify Menadione is reduced, increasing the risk of systemic toxicity. Dose reduction or alternative therapies are usually required.

Elderly Patients

Geriatric patients often have a higher prevalence of subclinical Vitamin K deficiency but are also more likely to be on anticoagulant therapy (like Warfarin). Dosing in the elderly should start at the lower end of the spectrum (2 mg) to avoid over-correction of clotting times, which could lead to thromboembolic events (clots).

If prescribed Menadione, follow these specific instructions to ensure safety and efficacy:

• Consistency: Take the medication at the same time every day to maintain stable levels in the bloodstream.
• With Food: While Menadione is more soluble than K1, taking it with a meal containing a small amount of fat can improve absorption.
• Swallow Whole: Do not crush or chew tablets unless specifically instructed by your pharmacist.
• Storage: Store at room temperature (68°F to 77°F), protected from light and moisture. Menadione is light-sensitive and can degrade if exposed to direct sunlight.

If you miss a dose of Menadione, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up, as this increases the risk of hemolytic anemia (destruction of red blood cells).

An overdose of Menadione is a medical emergency. Signs of toxicity include:

• Hemolysis: Rapid destruction of red blood cells leading to pale skin, fatigue, and dark urine.
• Jaundice: Yellowing of the eyes and skin.
• Liver Tenderness: Pain in the upper right abdomen.

In the event of a suspected overdose, contact a Poison Control Center or seek emergency medical attention immediately. Treatment typically involves supportive care and potentially blood transfusions if severe hemolysis has occurred.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop taking the medication without medical guidance, as this could lead to unexpected bleeding or clotting issues.

While Menadione is generally tolerated at very low doses, the following side effects are common when levels exceed the body's immediate requirement:

• Gastrointestinal Upset: Nausea, mild stomach cramping, or a strange taste in the mouth (dysgeusia) are frequently reported.
• Flushing: A temporary sensation of warmth or redness in the face and neck may occur shortly after administration.
• Dizziness: Some patients report mild lightheadedness, particularly when moving from a sitting to a standing position.

• Skin Rash: Pruritus (itching) or urticaria (hives) may develop in individuals with sensitivities to naphthoquinone derivatives.
• Headache: Persistent dull headaches have been noted in patients on long-term supplementation.
• Sweating: Increased perspiration (diaphoresis) unrelated to physical activity.

• Hemolytic Anemia: This is the most significant rare side effect in adults but becomes more common in those with G6PD deficiency. It involves the premature destruction of red blood cells.
• Hyperbilirubinemia: An accumulation of bilirubin in the blood, which can lead to jaundice.
• Hemoglobinuria: The presence of hemoglobin in the urine, giving it a dark or tea-colored appearance.

> Warning: Stop taking Menadione and call your doctor immediately if you experience any of the following serious adverse reactions:

• Signs of Hemolysis: Extreme fatigue, shortness of breath, rapid heart rate, and pale or yellowish skin. This suggests your red blood cells are breaking down faster than they can be replaced.
• Anaphylaxis: Severe allergic reaction characterized by swelling of the face, tongue, or throat, difficulty breathing, and a rapid drop in blood pressure.
• Hepatotoxicity: Signs of liver damage, including dark urine, persistent nausea, clay-colored stools, and severe pain in the upper right quadrant of the abdomen.
• Cyanosis: A bluish tint to the lips or fingernails, which may indicate methemoglobinemia (a condition where the blood cannot effectively carry oxygen).

Prolonged use of Menadione, especially at higher-than-recommended doses, can lead to chronic oxidative stress within the body. This may manifest as:

• Organ Damage: Potential long-term stress on the liver and kidneys due to the continuous processing of Menadione metabolites.
• Bone Mineral Density Changes: Because Vitamin K is involved in bone metabolism (via osteocalcin), chronic imbalance of Vitamin K forms could theoretically affect bone strength, though data on Menadione specifically is limited compared to K1 and K2.
• Blood Cell Abnormalities: Chronic low-level hemolysis may lead to compensatory erythroid hyperplasia (overproduction of red blood cell precursors in the bone marrow).

Currently, there is no official FDA Black Box Warning specifically for Menadione because it is not a widely marketed drug in the modern era. However, historical clinical literature and international health agencies emphasize a Strong Warning regarding its use in neonates.

Summary of Warning: Menadione must not be administered to newborn infants. Its use in this population is associated with a high incidence of hemolytic anemia, hyperbilirubinemia, and kernicterus, which can lead to permanent neurological damage or death. Phytonadione (Vitamin K1) is the only recommended form for Vitamin K prophylaxis in newborns.

Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular blood tests are often necessary to ensure the medication is working safely.

Menadione is a potent synthetic compound that carries significant risks if not used under strict medical supervision. Unlike natural Vitamin K found in leafy greens, Menadione can induce oxidative stress by depleting glutathione, a key antioxidant in the body. Patients must be aware that this medication is a precursor and its conversion process can vary significantly between individuals.

No FDA black box warnings currently exist for Menadione as it is not currently an FDA-approved primary therapy for human use in the U.S. (Phytonadione is the standard). However, historical warnings regarding Neonatal Toxicity are considered equivalent in clinical weight. The risk of brain damage (kernicterus) in infants is an absolute contraindication.

• Allergic Reactions: There is a risk of cross-sensitivity between Menadione and other naphthoquinones. If you have had a reaction to Vitamin K1 or K2, you should inform your doctor.
• G6PD Deficiency: This is a critical precaution. Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are at an extremely high risk of life-threatening hemolytic anemia if they take Menadione. The drug causes oxidative damage that G6PD-deficient cells cannot repair.
• Liver Disease: Menadione requires hepatic processing. In patients with cirrhosis or hepatitis, the drug may accumulate to toxic levels or fail to produce the desired clotting effect.
• Methemoglobinemia Risk: Menadione can oxidize hemoglobin to methemoglobin, which does not bind oxygen effectively. This can lead to tissue hypoxia (lack of oxygen).

Patients taking Menadione require regular clinical monitoring, including:

• Prothrombin Time (PT) / INR: To ensure the blood is clotting at the correct rate.
• Complete Blood Count (CBC): To monitor for signs of anemia or changes in red blood cell morphology.
• Bilirubin Levels: To check for signs of hemolysis or liver dysfunction.
• Liver Function Tests (LFTs): To monitor for potential hepatotoxicity.

Menadione is generally not expected to impair your ability to drive or operate heavy machinery. However, if you experience dizziness or flushing as a side effect, you should wait until these symptoms subside before engaging in potentially dangerous activities.

Alcohol consumption should be avoided or strictly limited while taking Menadione. Alcohol can interfere with the liver's ability to synthesize clotting factors and may exacerbate the gastrointestinal side effects of the medication. Furthermore, chronic alcohol use often leads to liver damage, which increases the risk of Menadione toxicity.

Do not stop taking Menadione suddenly unless instructed by your doctor. Stopping the medication abruptly can cause a sudden drop in clotting factor levels, putting you at risk for internal bleeding or excessive bruising. If the medication needs to be stopped, your healthcare provider will likely monitor your INR closely during the transition.

> Important: Discuss all your medical conditions, especially any history of blood disorders or liver disease, with your healthcare provider before starting Menadione.

• Warfarin (Coumadin): Menadione directly antagonizes the effects of Warfarin. Taking them together will render the anticoagulant therapy ineffective, potentially leading to life-threatening blood clots (thrombosis). This is an absolute contraindication unless the goal is specifically to reverse Warfarin-induced bleeding.
• Other Vitamin K Antagonists: Drugs like phenprocoumon or acenocoumarol should never be used with Menadione as they work in direct opposition.

• Bile Acid Sequestrants (e.g., Cholestyramine, Colestipol): These drugs bind to fats and fat-soluble vitamins in the gut, significantly reducing the absorption of Menadione. If both are necessary, Menadione should be taken at least 2 hours before or 4-6 hours after the sequestrant.
• Broad-Spectrum Antibiotics: Antibiotics can kill the gut bacteria that naturally produce Vitamin K2. While Menadione is a supplement, the loss of natural K2 may make the body more sensitive to changes in Menadione dosing, requiring more frequent INR monitoring.
• Mineral Oil: Regular use of mineral oil as a laxative can coat the intestines and prevent the absorption of fat-soluble vitamins like Menadione.

• Orlistat (Alli, Xenical): This weight-loss medication prevents fat absorption and can consequently reduce the amount of Menadione absorbed by the body.
• Salicylates (High-dose Aspirin): Large doses of aspirin can interfere with Vitamin K metabolism and may increase the requirement for Menadione.
• Corticosteroids: As the prompt mentions Corticosteroid [EPC] links, it is noted that steroids may alter the metabolic demand for Vitamin K, potentially affecting the efficacy of Menadione.

• Leafy Green Vegetables: Foods high in natural Vitamin K1 (spinach, kale, broccoli) can add to the effects of Menadione. While not dangerous, a sudden change in your intake of these foods can cause fluctuations in your INR levels.
• High-Fat Meals: Can increase the absorption of Menadione, potentially leading to higher-than-intended levels in the blood.
• Alcohol: As noted, alcohol can impair the liver's synthesis of clotting factors and increase toxicity risk.

• Vitamin E: High doses of Vitamin E (over 800 IU) can antagonize Vitamin K activity and may increase the risk of bleeding, opposing the intended effect of Menadione.
• St. John’s Wort: May induce liver enzymes (CYP3A4), which could theoretically speed up the metabolism of Menadione, though the clinical significance is not well-established.
• Ginkgo Biloba and Garlic: These supplements have mild blood-thinning properties and may interfere with the stabilization of clotting factors.

• Prothrombin Time (PT): Menadione will shorten the PT, which is the intended effect. However, this must be interpreted carefully in patients on anticoagulants.
• Liver Function Tests: Menadione can cause transient elevations in ALT, AST, and bilirubin, which may be misinterpreted as primary liver disease.
• Urinary Glucose Tests: Historical reports suggest that high doses of Menadione metabolites might interfere with certain older types of urine glucose tests.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even "natural" products can have significant interactions with Menadione's role in blood chemistry.

Menadione must NEVER be used in the following circumstances:

• Neonates (Newborn Infants): The risk of hemolytic anemia and kernicterus is too great. This is the most critical absolute contraindication in clinical practice.
• G6PD Deficiency: Patients with this genetic enzyme deficiency will suffer from oxidative hemolysis (red blood cell rupture) when exposed to Menadione.
• Hypersensitivity: Any known allergy to Menadione, Vitamin K1, or any component of the formulation.
• Severe Liver Failure: If the liver is unable to produce clotting factors due to end-stage disease (cirrhosis), Menadione will be ineffective and may only contribute to systemic toxicity.

Conditions requiring a careful risk-benefit analysis by a healthcare provider:

• Pregnancy (Near Term): Due to the risk of neonatal hemolysis and hyperbilirubinemia if the drug is still in the mother's system at the time of birth.
• Active Blood Clots: In patients with conditions like Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), administering a pro-coagulant like Menadione must be done with extreme caution to avoid worsening the clot.
• Renal Insufficiency: Reduced clearance of metabolites may necessitate lower doses and more frequent monitoring.
• Biliary Obstruction: While Menadione is absorbed better than K1 in these patients, the underlying lack of bile still hinders optimal uptake and processing.

Patients who have experienced allergic reactions to other naphthoquinones or synthetic vitamin analogs should be cautious. There is a potential for cross-reactivity with certain dyes and chemical allergens (Standardized Chemical Allergen [EPC]), as Menadione's structure is similar to various industrial quinones. If you have a history of contact dermatitis or systemic reactions to chemical dyes, discuss this with your doctor before using Menadione.

> Important: Your healthcare provider will evaluate your complete medical history, including genetic predispositions and current liver function, before prescribing Menadione.

Menadione is generally categorized as Pregnancy Category C (or X in specific historical contexts when used near term). There is evidence that Menadione can cross the placental barrier. Use during the third trimester is particularly hazardous because the fetal liver is immature and cannot process the drug, leading to a high risk of neonatal jaundice and hemolytic anemia. It should only be used during pregnancy if the potential benefit clearly outweighs the risk to the fetus, and natural Vitamin K1 is usually preferred.

Menadione is excreted into breast milk in small amounts. Because of the sensitivity of the infant's hematological system, there is a theoretical risk of inducing hemolytic anemia in the nursing infant. Most healthcare providers recommend using Vitamin K1 if supplementation is needed during lactation, or potentially suspending breastfeeding if Menadione therapy is required for the mother.

As previously emphasized, Menadione is contraindicated in neonates. For older children, the drug should only be used in rare cases of severe malabsorption where other forms of Vitamin K have failed. It is not approved for routine nutritional supplementation in children. Pediatric patients must be monitored daily for signs of hemolysis and jaundice.

Elderly patients are more likely to have age-related declines in renal and hepatic function, which can slow the clearance of Menadione. Furthermore, the risk of polypharmacy (taking multiple medications) is high in this group. Doctors must carefully screen for the use of anticoagulants or antiplatelet drugs. There is also an increased risk of thromboembolic complications in the elderly if Vitamin K levels are raised too rapidly.

In patients with impaired kidney function, the excretion of Menadione's water-soluble metabolites (glucuronides and sulfates) is delayed. While the parent compound is metabolized by the liver, the accumulation of these metabolites can lead to increased systemic toxicity. Dosing should be conservative, and kidney function (GFR) should be monitored throughout treatment.

In patients with hepatic impairment (Child-Pugh Class B or C), Menadione should be used with extreme caution. The liver is the primary site for both the action of Vitamin K (synthesis of clotting factors) and the metabolism of Menadione. If the liver is failing, the drug will not work and may cause further oxidative damage to hepatic cells. If PT/INR does not improve after 48 hours of therapy, it is a sign that liver damage is too severe for Vitamin K therapy to be effective.

> Important: Special populations require individualized medical assessment and often require more frequent blood monitoring than the general population.

Menadione (2-methyl-1,4-naphthoquinone) acts as a provitamin for the Vitamin K cycle. Its primary molecular mechanism involves serving as a precursor for menaquinone-4 (MK-4). In the presence of the enzyme UBIAD1, Menadione is converted into MK-4 in various tissues. Once converted, it acts as a cofactor for the enzyme gamma-glutamyl carboxylase (GGCX).

This enzyme utilizes the reduced form of Vitamin K (hydroquinone) to convert glutamic acid residues on Vitamin K-dependent proteins into gamma-carboxyglutamic acid. This modification is essential for the biological activity of clotting factors II, VII, IX, and X. Additionally, the prompt notes its activity as an Ammonium Ion Binding Agent [MoA], which relates to its role in nitrogen metabolism and its potential to influence pH balance in specific cellular environments.

• Dose-Response: The effect on Prothrombin Time (PT) is dose-dependent, but there is a ceiling effect; once all available glutamyl residues are carboxylated, additional Menadione does not further improve clotting.
• Onset of Action: Orally, the effect on clotting factors usually begins within 6 to 12 hours, with peak effect at 24 to 48 hours.
• Duration: The effects can last for several days as the newly synthesized clotting factors circulate in the blood.
• Tolerance: There is no known physiological tolerance to the Vitamin K-like effects of Menadione, though underlying disease progression can make the body less responsive.

| Parameter | Value |

|---|---|

| Bioavailability | 50% - 70% (increased with fat) |

| Protein Binding | 90% (primarily to albumin) |

| Half-life | 1 - 3 hours (parent compound) |

| Tmax | 1 - 2 hours |

| Metabolism | Hepatic (Alkylation to MK-4; Conjugation) |

| Excretion | Renal (60%), Fecal (40%) |

• Molecular Formula: C11H8O2
• Molecular Weight: 172.18 g/mol
• Solubility: Slightly soluble in water; soluble in alcohol, benzene, and vegetable oils.
• Structure: A polycyclic aromatic hydrocarbon consisting of a benzene ring fused to a quinone ring with a methyl group at the 2-position.

Menadione is classified as a Vitamin K Analog or Naphthoquinone derivative. Within the therapeutic area of hematology, it is a pro-coagulant. It is related to Phytonadione (K1) and Menaquinone (K2), but is distinguished by its synthetic nature and lack of a side chain.